2009
DOI: 10.1056/nejmoa0904554
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

106
1,399
13
44

Year Published

2011
2011
2019
2019

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 2,072 publications
(1,562 citation statements)
references
References 27 publications
106
1,399
13
44
Order By: Relevance
“…Cases that stained marginally above background using quantitative immunofluorescence were also sequenced, and EGFR was observed to be mutated in one case. Matching of EGFR concentrations with the corresponding mutational status revealed that all mutated cases had EGFR concentrations Ͼ1.466 ng/ g. Several studies have reported that the frequency of mutations in the tyrosine kinase domain of EGFR is 8% to 15% [27][28][29][30][31] in white patients with NSCLC, and 15% to 25% in white patients with histologic findings of adenocarcinoma. 10,31 However, this effort in two population-based predominantly white cohorts suggests a much lower mutation rate.…”
Section: Discussionmentioning
confidence: 97%
“…Cases that stained marginally above background using quantitative immunofluorescence were also sequenced, and EGFR was observed to be mutated in one case. Matching of EGFR concentrations with the corresponding mutational status revealed that all mutated cases had EGFR concentrations Ͼ1.466 ng/ g. Several studies have reported that the frequency of mutations in the tyrosine kinase domain of EGFR is 8% to 15% [27][28][29][30][31] in white patients with NSCLC, and 15% to 25% in white patients with histologic findings of adenocarcinoma. 10,31 However, this effort in two population-based predominantly white cohorts suggests a much lower mutation rate.…”
Section: Discussionmentioning
confidence: 97%
“…30 While approximately 10 % of Caucasians exhibit these mutations, upwards of 30-50 % of Asians harbor them. 31 EGFR mutations predict increased sensitivity to EGFR directed therapies, as well as standard chemotherapies. [30][31][32] In this study, Asian/PIs were more likely to be female and less likely to have a history of tobacco use.…”
Section: Discussionmentioning
confidence: 99%
“…31 EGFR mutations predict increased sensitivity to EGFR directed therapies, as well as standard chemotherapies. [30][31][32] In this study, Asian/PIs were more likely to be female and less likely to have a history of tobacco use. One could postulate that the high proportion of Asian/PI patients in our study possess the EGFR mutation and contribute to the higher survival compared to other racial/ethnic groups.…”
Section: Discussionmentioning
confidence: 99%
“…9 Similarly, in the BR.21 trial, EGFR mutational status did not show significant association with responsiveness to erlotinib. 10 Notably, the EGFR mutation incidence was only around 17À23% in Caucasians 10,11 and 40À60% in East Asians. 6,7,12 Therefore, identification of a novel biomarker other than EGFR mutation for predicting the efficacy of EGFR-TKIs will contribute to further individualizing NSCLC treatment.…”
Section: Introductionmentioning
confidence: 99%